PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1619-7089

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis ; day:24 ; month:9 ; year:2020 ; pages:1-11
European journal of nuclear medicine and molecular imaging ; (24.9.2020), 1-11

Creator: Seifert, Robert
Kessel, Katharina
Schlack, Katrin
Weber, Manuel
Herrmann, Ken
Spanke, Maximilian
Fendler, Wolfgang P.
Hadaschik, Boris
Kleesiek, Jens
Schäfers, Michael
Weckesser, Matthias
Boegemann, Martin
Rahbar, Kambiz

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00259-020-05040-1

URN: urn:nbn:de:101:1-2020111218001764602998

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:21 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Seifert, Robert
Kessel, Katharina
Schlack, Katrin
Weber, Manuel
Herrmann, Ken
Spanke, Maximilian
Fendler, Wolfgang P.
Hadaschik, Boris
Kleesiek, Jens
Schäfers, Michael
Weckesser, Matthias
Boegemann, Martin
Rahbar, Kambiz
SpringerLink (Online service)

Other Objects (12)

2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke

Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy

Evaluation of [68Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T

Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy

Ressourceneffizienz durch Produktionsplanung und Lean Production

Neuartiges Antriebskonzept zum Fahren, Lenken und Heben

The novel PROMISE framework for PSMA-PET reporting: ready for the clinical routine?

Factors predicting biochemical response and survival benefits following radioligand therapy with [Lu-177]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke

Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy

Evaluation of [68Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T

Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy

Ressourceneffizienz durch Produktionsplanung und Lean Production

Neuartiges Antriebskonzept zum Fahren, Lenken und Heben

The novel PROMISE framework for PSMA-PET reporting: ready for the clinical routine?

Factors predicting biochemical response and survival benefits following radioligand therapy with [Lu-177]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke

Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy

Evaluation of [68Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T

Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy

Ressourceneffizienz durch Produktionsplanung und Lean Production

Neuartiges Antriebskonzept zum Fahren, Lenken und Heben

The novel PROMISE framework for PSMA-PET reporting: ready for the clinical routine?

Factors predicting biochemical response and survival benefits following radioligand therapy with [Lu-177]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke

Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy

Evaluation of [68Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T

Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy

Ressourceneffizienz durch Produktionsplanung und Lean Production

Neuartiges Antriebskonzept zum Fahren, Lenken und Heben

The novel PROMISE framework for PSMA-PET reporting: ready for the clinical routine?

Factors predicting biochemical response and survival benefits following radioligand therapy with [Lu-177]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke

Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy

Evaluation of [68Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T

Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy

Ressourceneffizienz durch Produktionsplanung und Lean Production

Neuartiges Antriebskonzept zum Fahren, Lenken und Heben

The novel PROMISE framework for PSMA-PET reporting: ready for the clinical routine?

Factors predicting biochemical response and survival benefits following radioligand therapy with [Lu-177]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke

Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy

Evaluation of [68Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T

Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy

Ressourceneffizienz durch Produktionsplanung und Lean Production

Neuartiges Antriebskonzept zum Fahren, Lenken und Heben

The novel PROMISE framework for PSMA-PET reporting: ready for the clinical routine?

Factors predicting biochemical response and survival benefits following radioligand therapy with [Lu-177]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

Related objects

Reset password